PCSK9 and coronary atherosclerosis: Additionally, our analysis identified PCSK9 as causal for MI, with PCSK9 inhibitors such as Evolocumab, Alirocumab, RG.7652, and Bococizumab emerging as candidate drugs for treating MI.44 This is consistent with previous studies showing that PCSK9 inhibitors reduced the risk of coronary atherosclerosis.45,46